SOUTH SAN FRANCISCO, Calif., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc., a leader in innovative biologics, announced today that Lewis T. "Rusty" Williams, M.D., Ph.D., executive chairman and founder, and Julia P. Gregory, president and chief executive officer, will present at the Cowen and Company 31st Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts. Their presentation will take place on Monday, March 7, 2011, at 10:30 a.m., Eastern Standard Time. Ms. Gregory and Dr. Williams will present an overview of FivePrime and discuss the company's advancements in its clinical and preclinical development programs and pharmaceutical collaborations.
Five Prime Therapeutics, Inc. is a clinical-stage, privately held, biotechnology company discovering and developing innovative protein and antibody therapeutics. FivePrime is concluding testing of FP-1039, a first-in-class biologic, in a Phase 1 study for patients with solid tumors and has initiated a Phase 2 trial in a form of endometrial cancer. Using its novel high-tech discovery platform, FivePrime is building a strong pipeline of oncology, immunology and metabolic disease drug candidates. Its proprietary platform mines FivePrime's library of all the secreted and extracellular human proteins to screen for medically relevant new therapeutic proteins and antibody targets. FivePrime has active collaborations with Pfizer, Inc. in the fields of oncology and diabetes and GlaxoSmithKline for skeletal muscle disorders. For more information, visit .
The Five Prime Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8029
CONTACT: Five Prime Therapeutics, Inc. Two Corporate Drive South San Francisco, CA 94080 Debbie Tobin, 415-365-5721 Debbie.Tobin@fiveprime.com